Sean Madden

Sean leads the refinement of Lumicell’s products and regulatory strategy to achieve FDA approval, the development of the next generation of Lumicell products, the management of Medical Affairs for ongoing and upcoming clinical trials, and the strategy, stewardship and growth of Lumicell’s intellectual property portfolio. Sean received his B.S. in chemistry from The University of Florida and his Ph.D. in analytical chemistry from The University of Arizona. He is an author on over 80 academic papers and an inventor on more than 10 patents and active applications. Sean has worked in biomedical measurements and medical devices for over 20 years in areas including drug discovery, non-invasive glucose detection, arterial blood gas sensing, cervical cancer screening, ophthalmology imaging, and interventional cardiology imaging. As Vice President of Research and Clinical at Infraredx, he developed the technology and trial strategy that led to unique and groundbreaking label claims for the detection of vulnerable plaque, commercialization and use in over 20,000 patients worldwide, and the acquisition of the company by Nipro Corporation.